ACADIA Pharmaceuticals Inc. (ACAD) Upgraded at Zacks Investment Research

Cornelia Mascio
Mag 20, 2017

Invesco Ltd. (NYSE:IVZ) closed at $30.66 a share in the latest session and the stock value rose nearly 2.86% since the beginning of this year. Moore Terrence O also sold $311,490 worth of ACADIA Pharmaceuticals Inc.

Several hedge funds have recently added to or reduced their stakes in ACAD. California State Teachers Retirement System boosted its stake in ACADIA Pharmaceuticals by 6.7% in the third quarter. LLC now owns 5,629 shares of the biopharmaceutical company's stock valued at $179,000 after buying an additional 990 shares during the period. Norges Bank bought a new position in shares of ACADIA Pharmaceuticals during the fourth quarter worth about $24,050,000. BlackRock Fund Advisors now owns 2,554,287 shares of the biopharmaceutical company's stock valued at $81,252,000 after buying an additional 214,275 shares during the period. SG Americas Securities LLC now owns 13,077 shares of the biopharmaceutical company's stock valued at $416,000 after buying an additional 575 shares during the last quarter. Gilder Gagnon Howe & Co. Elliott Management Corp bought a new position in shares of ACADIA Pharmaceuticals during the first quarter worth about $26,726,000.

Analysts expect ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) opened at 27.06 on Thursday. These shares are worth $311,490 and were traded at $39.65 each. The company has a 50 day moving average of $33.85 and a 200-day moving average of $31.56. The firm's market cap is $3.29 billion. According to a recent spotcheck, company ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)'s 12 month volatility is presently 62.911800. The biopharmaceutical company reported ($0.72) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.01. The company had revenue of $15.30 million for the quarter, compared to the consensus estimate of $15.17 million. ACADIA Pharmaceuticals had a negative return on equity of 58.46% and a negative net margin of 4,427.79%. During the same quarter in the previous year, the company posted ($0.45) EPS. On average, analysts predict that ACADIA Pharmaceuticals Inc. will post ($2.83) earnings per share for the current fiscal year.

WARNING: "Macquarie Group Ltd". Roth Capital reinitiated ACADIA Pharmaceuticals Inc. "(ACAD) is Harvey Capital Management Inc.'s 8th Largest Position" was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this news story on another publication, it was illegally copied and republished in violation of USA & global copyright and trademark law. The original version of this piece can be read at https://www.thecerbatgem.com/2017/05/19/acadia-pharmaceuticals-inc-acad-position-maintained-by-macquarie-group-ltd-updated-updated.html. Price targets reflect what the analyst believes a stock will be worth four quarters into the future. Zacks Investment Research raised shares of ACADIA Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Tuesday, February 21st. Finally, Piper Jaffray Companies reiterated an overweight rating and set a $44.00 target price on shares of ACADIA Pharmaceuticals in a research report on Tuesday, February 7th. Vetr downgraded ACADIA Pharmaceuticals from a strong-buy rating to a buy rating and set a $37.64 target price on the stock.in a research note on Tuesday, January 31st. Jefferies Group LLC restated a "buy" rating and set a $47.00 price objective on shares of ACADIA Pharmaceuticals in a report on Wednesday, April 12th. HC Wainwright reissued a "buy" rating and issued a $60.00 target price on shares of ACADIA Pharmaceuticals in a research report on Friday, March 3rd.

Analysts have a mean recommendation of 2.50 on this stock (A rating of less than 2 means buy, "hold" within the 3 range, "sell" within the 4 range, and "strong sell" within the 5 range).

Brokerage houses, on average, are recommending investors to hold Invesco Ltd. (IVZ)'s shares projecting a $35.45 target price.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE